We demonstrated that patients with early ER+ BC with a high CCNE1/RB1 ratio have poorer OS compared to patients with a ratio <1, suggesting that this may represent a population of patients with an adverse outcome, which might mandate tailored therapeutic strategies. This evidence concerns the gene CCNE1 and breast cancer.